Show simple item record

dc.contributor.authorPawlyn, Cen_US
dc.contributor.authorGay, Fen_US
dc.contributor.authorLarocca, Aen_US
dc.contributor.authorRoy, Ven_US
dc.contributor.authorAilawadhi, Sen_US
dc.date.accessioned2018-07-05T11:01:51Z
dc.date.issued2016-06en_US
dc.identifier.citationCurrent hematologic malignancy reports, 2016, 11 (3), pp. 241 - 251en_US
dc.identifier.issn1558-8211en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1996
dc.identifier.eissn1558-822Xen_US
dc.identifier.doi10.1007/s11899-016-0323-4en_US
dc.description.abstractMultiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age. Yet, the population of elderly patients is heterogeneous: older patients are more likely to have comorbidities and frailties complicating both their initial diagnosis and subsequent management, but these are not consistent across the group. Furthermore, patients with comorbidities and frailty are generally underrepresented in clinical trials. Despite the survival of myeloma patients increasing following the introduction of novel agents, older patients continue to have worse outcomes with increased treatment-related toxicity. Treatment tolerability is not defined by age alone, rather a combination of age, physical function, cognitive function, and comorbidities. These factors all influence patients' tolerability of treatment and therefore treatment efficacy and should also be considered when reviewing the results of clinical trials. It is the nuances of determining how these factors interact that should influence initial treatment and ongoing management decisions and these will be discussed here.en_US
dc.formatPrinten_US
dc.format.extent241 - 251en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectMultiple Myelomaen_US
dc.subjectPeripheral Nervous System Diseasesen_US
dc.subjectHematologic Diseasesen_US
dc.subjectThalidomideen_US
dc.subjectDexamethasoneen_US
dc.subjectAntineoplastic Agents, Hormonalen_US
dc.subjectTreatment Outcomeen_US
dc.subjectDrug Therapy, Combinationen_US
dc.subjectActivities of Daily Livingen_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectVenous Thromboembolismen_US
dc.subjectProteasome Inhibitorsen_US
dc.titleNuances in the Management of Older People With Multiple Myeloma.en_US
dc.typeOther
rioxxterms.versionofrecord10.1007/s11899-016-0323-4en_US
rioxxterms.licenseref.startdate2016-06en_US
rioxxterms.typeotheren_US
dc.relation.isPartOfCurrent hematologic malignancy reportsen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.publication-statusPublisheden_US
pubs.volume11en_US
pubs.embargo.termsNot knownen_US
pubs.oa-locationhttps://iris.unito.it/retrieve/handle/2318/1617904/277857/Nuances%20in%20the%20Management%20of%20Older%20People%20With%20Multiple%20Myeloma.docxen_US
icr.researchteamMyeloma Biology and Therapeuticsen_US
dc.contributor.icrauthorPawlyn, Charlotteen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record